Glucagon-like peptide 1 receptor (GLP-1R) agonism is a validated approach for treating obesity. ECC-4703 is a small molecule and liver-targeting compound developed by Eccogene Co. Ltd. It is an ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Panelists discuss the expanding array of treatment options for metastatic hormone receptor–positive breast cancer, ...

Researchers in France have developed an antibody that blocks AMH, reversing PCOS symptoms in mice and opening the door to future human trials.

ASC-47 is a thyroid hormone receptor β agonist, muscle-preserving weight loss compound for treating obesity developed by Ascletis Pharma Inc. ASC-47 demonstrated a half-life of 26 and 40 days in ...

Hormone therapy may be used by young women to relieve symptoms from hormone-­related conditions, menopause, or gynecologic surgery. Long-term use of estrogen/progestin hormone therapy was positively ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

See why the ovary − often reduced to its reproductive role − menopause, age and estrogen affect a woman’s health throughout ...

A team from the Institut Curie, Inserm, and CNRS[1] has uncovered a new molecular mechanism, previously unknown, linking ...

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...